NCCN临床实践指南_造血生长因子(2019.V2)英文版

NCCN org Version 2 2019 03 27 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Version 2 2019 March 27 2019 Continue Hematopoietic Growth Factors Pamela Sue Becker MD PhD Chair Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Elizabeth A Griffiths MD Vice Chair Roswell Park Comprehensive Cancer Center Laura Alwan PharmD Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Kimo Bachiashvili MD University of Alabama at Birmingham Comprehensive Cancer Center Mona Benrashid PharmD Vanderbilt Ingram Cancer Center Anna Brown PharmD BCOP University of Michigan Rogel Cancer Center Peter Curtin MD UC San Diego Moores Cancer Center Shira Dinner MD Robert H Lurie Comprehensive Cancer Center of Northwestern University Ivana Gojo MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Wajih Zaheer Kidwai MD Yale Cancer Center Smilow Cancer Hospital Dwight D Kloth PharmD BCOP Fox Chase Cancer Center Eric H Kraut MD The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute Gary H Lyman MD MPH Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Mary Mably RPh BCOP University of Wisconsin Carbone Cancer Center Sudipto Mukherjee MD PhD MPH Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Shiven Patel MD MBA Huntsman Cancer Institute at the University of Utah Lia E Perez MD Moffitt Cancer Center Adam Poust PharmD University of Colorado Cancer Center Raajit Rampal MD PhD Memorial Sloan Kettering Cancer Center Vivek Roy MD Mayo Clinic Cancer Center Hope S Rugo MD UCSF Helen Diller Family Comprehensive Cancer Center Sepideh Shayani PharmD City of Hope National Medical Center Saroj Vadhan Raj MD The University of Texas MD Anderson Cancer Center Sumithira Vasu MBBS The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute Martha Wadleigh MD Dana Farber Brigham and Women s Cancer Center Peter Westervelt MD PhD Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine NCCN Jennifer Burns Lenora A Pluchino PhD Continue NCCN Guidelines Panel Disclosures Bone marrow transplantation Hematology Hematology oncology Internal medicine Medical oncology Pharmacology Discussion writing committee member NCCN Guidelines Version 2 2019 Hematopoietic Growth Factors Version 2 2019 03 27 19 2019 National Comprehensive Cancer Network NCCN All rights reserved NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Index Table of Contents Discussion Printed by Maria Chen on 4 28 2019 9 59 10 PM For personal use only Not approved for distribution Copyright 2019 National Comprehensive Cancer Network Inc All Rights Reserved Clinical Trials NCCN believes that the best management for any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged To find clinical trials online at NCCN Member Institutions click here nccn org clinical trials clinicians aspx NCCN Categories of Evidence and Consensus All recommendations are category 2A unless otherwise indicated See NCCN Categories of Evidence and Consensus NCCN Hematopoietic Growth Factors Panel Members Summary of the Guidelines Updates Management of Neutropenia Evaluation Risk Assessment and Prophylactic Use of Myeloid Growth Factors MGF 1 Additional Evaluation of Patient Risk Factors for Prophylactic Use of MGFs MGF 2 Secondary Prophylaxis with MGFs MGF 3 Therapeutic Use of MGFs MGF 4 Examples of Disease Settings and Chemotherapy Regimens with a High Intermediate Risk for Febrile Neutropenia MGF A G CSF for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery MGF B MGFs in Mobilization and Post Hematopoietic Cell Transplant MGF C Toxicity Risks with MGFs MGF D Management of Cancer and Chemotherapy Induced Anemia Evaluation of Anemia ANEM 1 Risk Assessment and Indications for Initial Transfusion in Acute Setting ANEM 2 Comparison of Risks and Goals of ESA Use Versus RBC Transfusion ANEM 3 Special Categories in Considering ESA Use ANEM 4 Evaluation of Iron Deficiency ANEM 5 Erythropoietic Therapy Dosing Titration and Adverse Effects ANEM A Parenteral Iron Preparations ANEM B Management of Cancer and Chemotherapy Induced Anemia for Patients Who Refuse Blood Transfusions ANEM C The NCCN Guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient s care o